+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Preventive Vaccines Market, 2020-2030

  • ID: 5093927
  • Report
  • April 2020
  • Region: Global
  • 248 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • BlueWillow Biologics
  • Fidelity Investments
  • JEMS Venture Capital
  • OrbiMed
  • Syngene
  • MORE

Overview

Vaccines are versatile preventive formulations that have, so far, enabled the global eradication of smallpox (1980) and polio (2015), which are both debilitating viral diseases. According to the WHO, currently, global vaccination coverage is nearly 85%. This is believed to be responsible for preventing close to three million deaths, which would have otherwise been caused by infectious diseases, such as chickenpox, diphtheria, measles, pneumonia, tetanus, and tuberculosis. In fact, recent immunization records indicate that more than 115 million children are immunized against diphtheria, tetanus and pertussis annually. However, vaccine development, especially against newly identified pathogens, is a challenging and time consuming process. For instance, authorities claim that although there are many initiatives investigating vaccines against the recently identified SARS-CoV-2 coronavirus strain, a viable vaccine is still a year away. Other barriers to vaccine development include lack of pathogen specific information, inadequate immunity (conferred by certain types of vaccines), existence of multiple pathogenic strains, and reversion potential (a phenomenon where a weakened pathogen intended for use as a vaccine, reverts to its infectious phenotype).

Despite the success achieved, so far, through vaccination, it is estimated that over 1.5 million children, under the age of five, die of vaccine-preventable diseases, every year. This is largely attributed to storage (loss of efficacy upon prolonged storage) and logistics-related (cold chain requirement) complexities, which impact adequate distribution and transportation of such medications to remote areas. Given the rate at which the global population is growing, the demand for vaccines is anticipated to increase significantly. In this regard, significant strides have been made in improving existing vaccine formulations, mostly focused on enhancing stability. Recent technical advances, especially in the field of biotechnology, have heralded a new era in immunogen design for vaccine development. Moreover, many developers claim to be working on next generation preventive vaccine candidates, such as recombinant vaccines, viral vector-based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunologic memory. Further, a variety of adjuvants (substances with the innate potential to augment an immune response) have been discovered and are now available for the development of more versatile vaccine formulations. Several regional government bodies and private investors are actively financing stakeholders in this industry. Given that in the recent past there has been a marked rise in new entrants in this field, we anticipate this market to witness substantial growth in the coming years.

Scope of the Report

The ‘Global Preventive Vaccines Market, 2020-2030’ report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain. The study also features a detailed analysis of the key drivers and trends related to this evolving segment of the pharmaceutical industry.

Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry/non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).
  • A competitiveness analysis of preventive vaccine developers, taking into consideration supplier strength (based on company size and its experience in this field) and pipeline strength (based on the number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indications evaluated, number of APIs evaluated and target patient population).
  • Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.
  • A detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s),  type of sponsor/collaborator, leading industry sponsors/collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.
  • An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided information on investments made and recent developments in the domain.
  • An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines.
  • A case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell/virus banking, analytical development/testing, formulation, process development, fill/finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for preventive vaccines over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), [B] type of vaccine (pneumococcal conjugate vaccine, human papilloma virus vaccine, influenza vaccine, rotavirus vaccine, varicella vaccine, DTP-HepB-Hib vaccine, meningococcal group A, C, Y and W-135 vaccine and others), [C] type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), [D] target patient population (pediatric and adults) and [E] key geographical regions, covering North America (the US, Mexico and Canada), Europe (Spain, the UK, Italy, France, Germany and rest of Europe), Asia Pacific (India, China, Australia and rest of Asia Pacific), and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • BlueWillow Biologics
  • Fidelity Investments
  • JEMS Venture Capital
  • OrbiMed
  • Syngene
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Preventive Vaccines
3.2.1. Classification of Vaccines
3.2.1.1. Live, Attenuated Vaccines
3.2.1.2. Inactivated Vaccines
3.2.1.3. Subunit Vaccines
3.2.1.4. Toxoid Vaccines
3.2.1.5. DNA Vaccines
3.2.2. Key Components of a Vaccine Formulation
3.2.3. Production of Vaccines using Different Expression Systems
3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.2.3.2. Mammalian Expression Systems
3.2.3.3. Avian Expression Systems
3.2.3.4. Plant Expression Systems
3.2.3.5. Bacterial Expression Systems
3.2.3.6. Yeast Expression Systems
3.2.3.7. Insect Expression System
3.2.4. Routes of Vaccine Administration
3.2.4.1. Intramuscular Route
3.2.4.2. Subcutaneous Route
3.2.4.3. Oral Route
3.2.4.4. Intranasal Route
3.2.4.5. Intradermal Route
3.2.4.6. Inhalation
3.2.5. Clinical Development and Approval of Vaccines
3.2.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Preventive Vaccines: Overall Market Landscape
4.2.1. Marketed Vaccines Landscape
4.2.2. Clinical-Stage Vaccines Landscape
4.2.2.1. Analysis by Type of Developer
4.2.2.2. Analysis by Phase of Development
4.2.2.3. Analysis by Route of Administration
4.2.2.4. Analysis by Type of Vaccine API
4.2.2.5. Analysis by Dosage Form
4.2.2.6. Analysis by Dosage
4.2.2.7. Analysis by Target Disease Indication
4.2.2.8. Analysis by Target Patient Population
4.2.2.9. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
4.2.2.10. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Competitiveness Analysis: Preventive Vaccine Developers
5.4.1. Preventive Vaccine Developers based in North America
5.4.2. Preventive Vaccine Developers based in Europe
5.4.3. Preventive Vaccine Developers based in Asia Pacific

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Bio Farma
6.2.1. Company Overview
6.2.2. Preventive Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Emergent BioSolutions
6.3.1. Company Overview
6.3.2. Preventive Vaccines Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. GC Pharma
6.4.1. Company Overview
6.4.2. Preventive Vaccines Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. GlaxoSmithKline
6.5.1. Company Overview
6.5.2. Preventive Vaccines Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Janssen
6.6.1. Company Overview
6.6.2. Preventive Vaccines Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Merck
6.7.1. Company Overview
6.7.2. Preventive Vaccines Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Novavax
6.8.1. Company Overview
6.8.2. Preventive Vaccines Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Pfizer
6.9.1. Company Overview
6.9.2. Preventive Vaccines Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Sanofi Pasteur
6.10.1. Company Overview
6.10.2. Preventive Vaccines Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. Valneva
6.11.1. Company Overview
6.11.2. Preventive Vaccines Portfolio
6.11.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Preventive Vaccines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Enrolled Patient Population and Trial Registration Year
7.3.3. Analysis by Trial Phase
7.3.4. Analysis by Trial Recruitment Status
7.3.5. Analysis by Study Design
7.3.6. Analysis by Trial Focus Area
7.3.7. Analysis by Type of Preventive Vaccine (based on Pathogen)
7.3.8. Analysis by Target Disease Indication
7.3.9. Analysis by Type of Sponsor / Collaborator
7.3.10. Leading Industry Players: Analysis by Number of Registered Trials
7.3.11. Geographical Analysis by Number of Registered Trials
7.3.12. Geographical Analysis by Enrolled Patient Population
7.3.13. Geographical Analysis by Trial Recruitment Status

8. ONGOING VACCINE DEVELOPMENT INITIATIVES FOR COMPLEX CONDITIONS
8.1. Chapter Overview
8.2. Coronavirus Disease (COVID-19)
8.2.1. Disease Overview
8.2.2. Global Burden of COVID-19
8.2.3. Current Treatment Landscape
8.2.4. Preventive Vaccines for COVID-19
8.2.4.1. Historical Background of COVID-19 Vaccine Research
8.2.4.2. COVID-19 and Affiliated Research Landscape
8.2.5. Funding Instances
8.2.6. Recent Developments
8.3. Ebola Virus Disease (EVD)
8.3.1. Disease Overview
8.3.2. Global Burden of EVD
8.3.3. Current Treatment Landscape
8.3.4. Preventive Vaccines for EVD
8.3.4.1. Historical Background of Ebola Virus Vaccine Research
8.3.4.2. Anti-Ebola Virus Vaccines and Affiliated Research Landscape
8.3.5. Funding Instances
8.3.6. Recent Developments
8.4. HIV/AIDS
8.4.1. Disease Overview
8.4.2. Global Burden of HIV/AIDS
8.4.3. Current Treatment Landscape
8.4.4. Preventive Vaccines for HIV/AIDS
8.4.4.1. Historical Background of HIV/AIDS Vaccine Research
8.4.4.2. Anti-HIV Vaccines and Affiliated Research Landscape
8.4.5. Funding Instances
8.4.6. Recent Developments
8.5. Malaria
8.5.1. Disease Overview
8.5.2. Global Burden of Malaria
8.5.3. Current Treatment Landscape
8.5.4. Preventive Vaccines for Malaria
8.5.4.1. Historical Background of Malaria Vaccine Research
8.5.4.2. Anti-Malaria Vaccines and Affiliated Research Landscape
8.5.5. Funding Instances
8.5.6. Recent Developments
8.6. Zika Virus Infection
8.6.1. Disease Overview
8.6.2. Global Burden of Zika Virus Infection
8.6.3. Current Treatment Landscape
8.6.4. Preventive Vaccines for Zika Virus Infection
8.6.4.1. Historical Background of Zika Virus Vaccine Research
8.6.4.2. Anti-Zika Virus Vaccines and Affiliated Research Landscape
8.6.5. Funding Instances
8.6.6. Recent Developments

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Preventive Vaccines: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different Types of Vaccine API
9.3.5. Analysis by Focus Area
9.3.6. Analysis by Amount Invested by Different Type of Investors
9.3.7. Most Active Players: Analysis by Number of Funding Instances
9.3.8. Most Active Investors: Analysis by Number of Funding Instances
9.3.9. Analysis by Geography
9.3.9.1. Continent-wise Analysis
9.3.9.2. Country-wise Analysis

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Preventive Vaccines Market, 2020-2030
10.3.1. Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration
10.3.2. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine
10.3.3. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API
10.3.4. Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population
10.3.5. Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions
10.3.5.1. Preventive Vaccines Market in North America, 2020-2030
10.3.5.1.1. Preventive Vaccines Market in the US, 2020-2030
10.3.5.1.2. Preventive Vaccines Market in Mexico, 2020-2030
10.3.5.1.2. Preventive Vaccines Market in Canada, 2020-2030
10.3.5.2. Preventive Vaccines Market in Europe, 2020-2030
10.3.5.2.1. Preventive Vaccines Market in Spain, 2020-2030
10.3.5.2.2. Preventive Vaccines Market in the UK, 2020-2030
10.3.5.2.3. Preventive Vaccines Market in Italy, 2020-2030
10.3.5.2.4. Preventive Vaccines Market in France, 2020-2030
10.3.5.2.5. Preventive Vaccines Market in Germany, 2020-2030
10.3.5.2.6. Preventive Vaccines Market in Rest of Europe, 2020-2030
10.3.5.3. Preventive Vaccines Market in Asia Pacific, 2020-2030
10.3.5.3.1. Preventive Vaccines Market in India, 2020-2030
10.3.5.3.2. Preventive Vaccines Market in China, 2020-2030
10.3.5.3.3. Preventive Vaccines Market in Australia, 2020-2030
10.3.5.3.4. Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030
10.3.5.4. Preventive Vaccines Market in Rest of the World, 2020-2030
 
11. CASE-IN-POINT: CONTRACT MANUFACTURING OF VACCINES
11.1. Chapter Overview
11.2. Vaccine Contract Manufacturing
11.2.1. Addressing an Unmet Need
11.2.2. Commonly Outsourced Operations
11.2.3. Selecting a CMO Partner
11.2.4. Advantages of Outsourcing Manufacturing Services
11.2.5. Associated Risks and Challenges
11.3. Vaccine Contract Manufacturing: Overall Market Landscape
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Location of Headquarters
11.3.5. Analysis by Location of Manufacturing Facilities
11.3.6. Analysis by Type of Service(s) Offered
11.3.7. Analysis by Expression System Used
11.3.8. Analysis by Type of Vaccine Manufactured
11.3.9. Analysis by Type of Vaccine Manufactured and Location of Headquarters

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Alopexx
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Daniel R. Vlock, Chief Executive Officer

14. APPENDIX 1: TABULATED DATA

Note: Product cover images may vary from those shown
3 of 4
  • 3P Biopharmaceuticals
  • Abbott Biologicals
  • AbbVie Contract Manufacturing
  • Aberdeen Proving Ground
  • ABL
  • Abu Dhabi Investment Authority
  • Abzena
  • Adimmune
  • Adjuvant Capital
  • Advagene Biopharma
  • Affinivax
  • AJ Biologics
  • AJ Vaccines
  • Ajinomoto Bio-Pharma Services
  • Alexandria Venture Investments
  • Alopexx Vaccine
  • Altimmune
  • AmbioPharm
  • AMRI
  • Anaxago
  • Angels High Tech Investments
  • Anhui Zhifei Longcom Biologic Pharmacy
  • ARCH Venture Partners
  • ArrowMark Partners
  • Astellas Pharma
  • Atlantic Methanol Production Company
  • Auro Vaccines
  • Avid Bioservices
  • AVIR Green Hills Biotechnology
  • aws Gründerfonds
  • Barr Laboratories
  • Batavia Biosciences
  • Bavarian Nordic
  • Baxter BioPharma Solutions
  • Baylor College of Medicine
  • BB Biotech
  • Beijing Center for Disease Control and Prevention
  • Beijing Institute of Biological Products
  • Beijing Minhai Biotechnology
  • Beijing Zhifei Lvzhu Biopharmaceutical
  • Bharat Biotech
  • Bharat Serums and Vaccine
  • Bill & Melinda Gates Foundation
  • Bilthoven Biologicals
  • BINEX
  • Bio Elpida
  • Bio Farma
  • BioCell
  • BioConnections
  • Biofabri
  • Biological E.
  • Bio-Manguinhos
  • BioMARC
  • Biomay
  • Biomedical Advanced Research and Development Authority
  • BioMedPartners
  • BiondVax Pharmaceuticals
  • BioReliance
  • BioTechLogic
  • BioTechnique
  • BlueWillow Biologics
  • Boehringer Ingelheim BioXcellence
  • Boehringer Ingelheim Venture Fund
  • Boryung Pharmaceutical
  • Brammer Bio
  • Bryllan
  • Bul Bio-National Center of Infectious and Parasitic Diseases
  • Burrard Pharmaceuticals
  • Cadila Healthcare
  • CanSino Biologics
  • CARBOGEN AMCIS
  • CARB-X
  • Catalent
  • Center for Genetic Engineering and Biotechnology
  • Century Pharmaceuticals
  • CEPI
  • Cerberus Capital Management
  • CEVEC Pharmaceuticals
  • Charles River Laboratories
  • Chengdu Institute of Biological Products
  • Chiron Behring Vaccines
  • Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences
  • CJ HealthCare
  • Cobra Biologics
  • Codagenix
  • Consort Medical
  • CRG
  • CSL
  • CureVac
  • Curevo
  • Cytovance Biologics
  • Dalton Pharma Services
  • Danish Government
  • Danish Innovation Foundation
  • Dartmouth-Hitchcock Medical Center
  • Deerfield Management
  • Department of the Army
  • Division of AIDS
  • Duke Human Vaccine Institute
  • Dynavax Technologies
  • EDBI
  • EirGenix
  • Emergent BioSolutions
  • Emergent Product Development Gaithersburg
  • Emergex Vaccines
  • Ethiopian Government
  • EuBiologics
  • Euclidean Capital
  • Eurofins Amatsigroup
  • Eurogentec
  • EDCTP
  • European Investment Bank
  • European Union
  • Eveliqure Biotechnologies
  • Farallon Capital
  • Federal State Budgetary Scientific Institution
  • FF DSF VI
  • Fidelity Investments
  • Fiocruz
  • FluGen
  • Forbion
  • Fort Detrick
  • Fortune Capital
  • FUJIFILM Diosynth Biotechnologies
  • FundRx
  • Future Industry Investment Fund
  • Gamaleya Research Institute of Epidemiology and Microbiology
  • GC Cell
  • GC Pharma
  • GeneMatrix
  • GeneOne Life Science
  • GenIbet Biopharmaceuticals
  • Georgia Institute of Technology
  • Gilead
  • GlaxoSmithKline
  • Global Health Investment Fund
  • Goldstone Investment
  • Gopher Asset Management
  • Government of the Republic of Equatorial Guinea
  • Government of Norway
  • GPO-MBP
  • GreenPak Biotech
  • GreenSignal Bio Pharma
  • GTP Technology
  • GV
  • Hadean Ventures
  • Haffkine Bio-Pharmaceutical
  • HALIX
  • Hawaii Biotech
  • HBM Partners
  • Health Biotech
  • HealthCap
  • Hillhouse Capital
  • Hong Kong Institute of Biotechnology
  • HOOKIPA Pharma
  • Hualan Biological Bacterin
  • Icahn School of Medicine at Mount Sinai
  • IDT Biologika
  • ILiAD Biotechnologies
  • Il-Yang Pharmaceutical
  • Immunobiological Technology Institute (BioManguinhos)
  • Imperial College London
  • Indian Immunologicals
  • Infectious Disease Research Institute
  • Innovate UK
  • Inovio Pharmaceuticals
  • Institut Pasteur de Dakar
  • Institute for Biomedical Science
  • Institute of Vaccines and Medical Biologicals
  • Instituto Nacional de Saúde
  • Intas
  • Integrity Bio
  • International AIDS Vaccine Initiative
  • International Centre for Diarrhoeal Disease Research, Bangladesh
  • International Vaccine Institute
  • Invus
  • Israel Innovation Authority
  • Israel Investment Center
  • Jack Ma Foundation
  • Janssen
  • Japan Bank for International Cooperation
  • Japan BCG Laboratory
  • JEMS Venture Capital
  • Jiangsu Provincial Center for Disease Control and Prevention
  • JN-International Medical
  • Johnson & Johnson Innovation
  • Joint Program Executive Office for Chemical and Biological Defense
  • JSR
  • Jubilant HollisterStier
  • Julius Baer
  • Kemwell Biopharma
  • King Abdullah International Medical Research Center
  • Knox
  • Korea Investment Partners
  • LF Investment
  • LG Chem
  • Lilly Asia Ventures
  • LimmaTech Biologics
  • Line Moon Ventures
  • Liontrust
  • Lonza
  • LuinaBio
  • Mahidol University
  • Marathon Oil Corporation
  • Massachusetts General Hospital
  • MassBiologics
  • MCM Vaccine
  • Ministry of Health of the Russian Federation
  • Medicago
  • Medical Countermeasure Systems–Joint Vaccine Acquisition Program
  • Medigen Vaccine Biologics
  • MedImmune
  • Meissa Vaccines
  • Merck
  • Meridian Life Science
  • MIKROGEN
  • MinervaX
  • Ministry of Economic Affairs
  • Ministry of Foreign Affairs (Netherlands)
  • Moderna
  • Morningside Ventures
  • MRC/UVRI Uganda Research Unit on AIDS
  • MSD Wellcome Trust Hilleman Laboratories
  • Mymetics
  • Natick Contracting Division
  • National Authority for Technological Innovation
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • National Vaccine & Serum Institute
  • Network-1 Technologies
  • Nitto Avecia Pharma Services
  • Noble Energy
  • North Coast Technology Investors
  • Noshaq
  • Nova Immunotherapeutics
  • Novartis
  • Novartis Venture Fund
  • Novasep
  • Novavax
  • Novo Holdings
  • Novo Seeds
  • NPO Petrovax Pharm
  • Omnes Capital
  • OPKO Health
  • OrbiMed
  • Organon Teknika
  • Osivax
  • Oxford Sciences Innovation
  • Panacea Biotec
  • PATH
  • Perceptive Advisors
  • Pfizer
  • Pfizer CentreOne
  • Pictet
  • Pierre Fabre
  • Piramal Pharma Solutions
  • PnuVax
  • Polymun Scientific
  • Porton Biopharma
  • Premas Biotech
  • ProBioGen
  • Profectus BioSciences
  • Protein Sciences
  • PX’Therapeutics
  • Qiming Venture Partners
  • Redmile Group
  • Redmont Capital
  • Reliance Life Sciences
  • Research Foundation for Microbial Diseases, Osaka University
  • Richter-Helm Biologics
  • Rommelag CMO
  • RTW Investments
  • Russian Academy of Sciences
  • Sabin Vaccine Institute
  • Samsara BioCapital
  • Sanaria
  • Sanofi Pasteur
  • Scandinavian Biopharma
  • Scripps Research Institute
  • SDS Capital Partners
  • Seedlings Life Science Ventures
  • SEEK
  • Seqirus
  • Sequoia
  • Sequoia China
  • Serum Institute of India
  • Shanghai Bovax Biotechnology
  • Shantha Biotechnics
  • Sinovac Biotech
  • Sirona Capital
  • SK Bioscience
  • Sofinnova Partners
  • State of Wisconsin Investment Board
  • Sunstone Capital
  • Sunstone Life Science Ventures
  • Swissfillon
  • Syngene
  • Takeda
  • Takeda Ventures
  • Teva Pharmaceuticals
  • Texas Biomedical Research Institute
  • The Peter Doherty Institute for Infection and Immunity
  • The Wistar Institute
  • Themis Bioscience
  • Thermo Fisher Scientific
  • Topspin Partners
  • Truffle Capital
  • UK Government
  • UK Research and Innovation
  • Univercells
  • University Health Network
  • University Medical Center Hamburg-Eppendorf
  • University of Amsterdam
  • University of Antwerp
  • University of California
  • University of Georgia
  • University of Maryland
  • University of Michigan
  • University of Minnesota
  • University of Oxford
  • University of Washington
  • US Agency for International Development
  • US Army Contracting Command
  • US Army Medical Research and Materiel Command
  • US Centers for Disease Control and Prevention
  • US Defense Advanced Research Projects Agency
  • US Defense Threat Reduction Agency
  • US Department of Agriculture
  • US Department of Defense
  • Vaccitech
  • Valneva
  • Vaxart
  • Vaxine
  • VaxNewMo
  • Vaxxilon
  • VBI Vaccines
  • Ventech
  • Venture Investors
  • Vetter Pharma
  • VGXI
  • Vibalogics
  • Vickers Venture Partners
  • Viking Global Investors
  • Wacker Biotech
  • Waisman Biomanufacturing
  • Wallace Pharmaceuticals
  • Wellington Partners Life Sciences
  • Wisconsin Alumni Research Foundation
  • WuXi Biologics
  • Wuxi Griffin
  • Wyeth Pharmaceuticals
  • Xiamen University
  • X-Vax Technology
Note: Product cover images may vary from those shown
4 of 4

 

 

Loading
LOADING...

Adroll
adroll